Kiora Pharmaceuticals, Inc.
2.5300+0.08 (+3.05%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · KPRX · USD
Key Stats
Market Cap
8.69MP/E (TTM)
-Basic EPS (TTM)
-3.36Dividend Yield
0%Recent Filings
8-K
Kiora updates pipeline progress
Kiora Pharmaceuticals updated its investor presentation on August 13, 2025, highlighting progress on vision-restoring KIO-301 for retinitis pigmentosa and anti-inflammatory KIO-104 for retinal diseases. With $20.7 million in cash extending runway to late 2027, the company eyes Phase 2 readouts in early 2027 via partnerships with Théa and Senju, potentially unlocking up to $285 million in milestones plus royalties exceeding 20%. KIO-301 reanimates retinas in trials. Forward-looking risks include regulatory hurdles and trial delays.
8-K
Kiora advances Phase 2 trials
Kiora Pharmaceuticals advanced its retinal disease pipeline in Q2 2025, initiating Phase 2 KLARITY trial for KIO-104 in inflammation and ABACUS-2 for KIO-301 in retinitis pigmentosa vision restoration. The company secured a Senju option agreement for KIO-301 Asia commercialization, potentially worth $110 million plus royalties, while extending KIO-104 patent exclusivity to 2043. Cash reserves hit $20.7 million, funding operations into late 2027 beyond trial readouts. Net loss held steady at $2.2 million.
10-Q
Q2 FY2025 results
Kiora Pharmaceuticals posted a Q2 net loss of $2.2M, up slightly from $2.2M last year, with no revenue after recognizing the full $16M TOI collaboration upfront in Q1 2024; YTD, the net loss hit $4.3M versus $11.2M profit in 2024, driven by that one-time gain. Operating expenses dipped 7% q/q to $2.4M, fueled by higher R&D on KIO-301 trials offset by $1.7M TOI reimbursements, while gross margins aren't applicable in this pre-revenue phase. Cash burned $6.5M in operations but ended at $1.0M plus $19.6M short-term investments, bolstered by a $10M UBS credit line (unused at quarter-end) and warrant exercises netting $0.3M; free cash flow isn't disclosed in the 10-Q. In May, Kiora inked a $1.25M option deal with Senju for Asian KIO-301 rights, potentially unlocking $110M more if exercised. Cash runway stretches to late 2027. Regulatory hurdles could delay approvals.
8-K
Annual meeting results announced
Kiora Pharmaceuticals held its annual meeting on June 4, 2025, where stockholders elected Carmine Stengone and Brian M. Strem, Ph.D. as Class I directors for three-year terms ending in 2028. They also approved executive compensation on a non-binding basis and ratified Haskell & White LLP as auditors for the fiscal year through December 31, 2025. Votes for directors topped 1.1 million each, with strong support overall. Governance stays steady.
8-K
Kiora-Senju KIO-301 Asia option
Kiora Pharmaceuticals inked an exclusive option deal with Senju Pharmaceutical on May 30, 2025, for KIO-301 in key Asian markets like Japan and China, targeting retinitis pigmentosa and other eye diseases. Senju pays $1.25 million upfront, with potential value hitting $110 million in milestones plus high single- to high-teen royalties if exercised post-ABACUS-2 Phase 2 data. This bolsters Kiora's cash into late 2027. Option exercise hinges on topline results.
ALDX
Aldeyra Therapeutics, Inc.
5.05-0.09
KALA
KALA BIO, Inc.
0.80-0.03
KLRS
Kalaris Therapeutics, Inc.
4.87-0.13
KOD
Kodiak Sciences Inc
18.93-0.32
KYMR
Kymera Therapeutics, Inc.
60.03-1.92
OCS
Oculis Holding AG
21.55+0.55
OKYO
OKYO Pharma Limited
2.72+0.17
OPT
Opthea Limited
3.41+0.00
UNBX
Unity Biotechnology, Inc.
0.06+0.00
ZVRA
Zevra Therapeutics, Inc.
10.12-0.96